Clinical Trial Update: Tumor Response to Pemetrexed Disodium in Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Enrolled in Clinical Trial MCCRC-RC0524

View source ↗

Summary

The clinical trial MCCRC-RC0524 evaluating pemetrexed disodium in stage III/IV non-small cell lung cancer reports tumor responses observed in enrolled patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Pemetrexed disodium (Pemetrexed disodium)

Snippet

Sponsor: Mayo Clinic | Conditions: Lung Cancer | Status: COMPLETED